This big pharma stock still faces significant challenges in the new year.

Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...

Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact. Yet, benefits to consumers will be modest. Furthermore, prices for ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if ...